Disease Progression Modeling: Key Concepts and Recent Developments

Disease modeling involves the use of mathematical functions to describe quantitatively the time course of disease progression. In order to characterize the natural progression of disease, these models generally incorporate longitudinal data for some biomarker(s) of disease severity or can incorporate more direct measures of disease severity. Disease models are also often linked to pharmacokinetic–pharmacodynamic models so that the influence of drug treatment on disease progression can be quantified and evaluated. Regulatory agencies have embraced disease progression models as powerful tools that can be used to improve drug development productivity. This article provides a brief overview of key concepts in disease progression modeling followed by illustrative examples from models for Alzheimer’s disease. Finally, recent novel applications in which disease progression models have been linked to cost-effectiveness analysis and genomic analysis are described.

[1]  Maurizio Fava,et al.  Amyotrophic lateral sclerosis disease progression model , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[2]  R. Gomeni,et al.  Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. , 2007, British journal of clinical pharmacology.

[3]  Karline Soetaert,et al.  Solving Differential Equations in R: Package deSolve , 2010 .

[4]  K. Peace,et al.  The effect of tacrine and lecithin in Alzheimer's disease , 2004, European Journal of Clinical Pharmacology.

[5]  D. Mould Models for Disease Progression: New Approaches and Uses , 2012, Clinical pharmacology and therapeutics.

[6]  Michael Krams,et al.  Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  Jan A M Raaijmakers,et al.  Development of a Framework for Cohort Simulation in Cost-Effectiveness Analyses Using a Multistep Ordinary Differential Equation Solver Algorithm in R , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[8]  J. Schellens,et al.  Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin , 2015, CPT: pharmacometrics & systems pharmacology.

[9]  C. Peck,et al.  Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model , 2000, Clinical pharmacology and therapeutics.

[10]  V. Narayan,et al.  Disease progression model for Clinical Dementia Rating–Sum of Boxes in mild cognitive impairment and Alzheimer’s subjects from the Alzheimer’s Disease Neuroimaging Initiative , 2014, Neuropsychiatric disease and treatment.

[11]  Jon Neville,et al.  Development of a unified clinical trial database for Alzheimer's disease , 2015, Alzheimer's & Dementia.

[12]  Danny Chen,et al.  An updated Alzheimer’s disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM , 2014, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  Jae Eun Ahn,et al.  Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[14]  Hiroaki Kitano,et al.  The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..

[15]  J. Nutt,et al.  Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  A. Pestronk,et al.  Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. , 1991, Archives of neurology.

[17]  J. Nutt,et al.  Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. , 2012, British journal of clinical pharmacology.

[18]  E. Gamazon,et al.  Genome-wide interrogation of longitudinal FEV1 in children with asthma. , 2014, American journal of respiratory and critical care medicine.

[19]  MC Peterson,et al.  FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.

[20]  Janet Woodcock,et al.  The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.

[21]  K E Peace,et al.  Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. Pichler,et al.  INTERACTION INITIATIVES BETWEEN REGULATORY, HEALTH TECHNOLOGY ASSESSMENT AND COVERAGE BODIES, AND INDUSTRY , 2012, International Journal of Technology Assessment in Health Care.

[23]  Joseph Beyene,et al.  Longitudinal Data Analysis in Genome‐Wide Association Studies , 2014, Genetic epidemiology.

[24]  D. Mould Developing Models of Disease Progression , 2006 .

[25]  Kaori Ito,et al.  Disease progression meta-analysis model in Alzheimer's disease , 2010, Alzheimer's & Dementia.

[26]  D Polhamus,et al.  The future is now: Model‐based clinical trial design for Alzheimer's disease , 2015, Clinical pharmacology and therapeutics.

[27]  K E Peace,et al.  Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Weuve,et al.  2016 Alzheimer's disease facts and figures , 2016 .

[29]  Matthew M Riggs,et al.  A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. , 2010, Bone.

[30]  William J. Jusko,et al.  Pharmacokinetic/Pharmacodynamic Modelling in Diabetes Mellitus , 2008, Clinical pharmacokinetics.

[31]  M. Gibbs,et al.  Model‐Based Meta‐Analysis for Comparative Efficacy and Safety: Application in Drug Development and Beyond , 2011, Clinical pharmacology and therapeutics.

[32]  Lawrence J Lesko,et al.  Quantitative disease, drug, and trial models. , 2009, Annual review of pharmacology and toxicology.

[33]  Maciej J. Swat,et al.  The impact of mathematical modeling on the understanding of diabetes and related complications , 2013, CPT: pharmacometrics & systems pharmacology.

[34]  J. Schellens,et al.  Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin , 2015, CPT: pharmacometrics & systems pharmacology.

[35]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[36]  I. Lombardo,et al.  The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study , 2015, Alzheimer's & Dementia.

[37]  B P Booth,et al.  Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development , 2009, Clinical pharmacology and therapeutics.

[38]  Jan Fagerberg,et al.  Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Zheyang Wu,et al.  Longitudinal Data Analysis for Genetic Studies in the Whole‐Genome Sequencing Era , 2014, Genetic epidemiology.

[40]  Kaori Ito,et al.  Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database , 2011, Alzheimer's & Dementia.

[41]  L. Friberg,et al.  The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia , 2012, Cancer Chemotherapy and Pharmacology.

[42]  Jon Neville,et al.  Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database. , 2013, Journal of Alzheimer's disease : JAD.

[43]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[44]  A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling , 2015, Journal of Pharmacokinetics and Pharmacodynamics.

[45]  N Franklin Adkinson,et al.  Long-term effects of budesonide or nedocromil in children with asthma. , 2000, The New England journal of medicine.

[46]  S. Potkin,et al.  Placebo response trajectories in short-term and long-term antipsychotic trials in schizophrenia , 2011, Schizophrenia Research.

[47]  D. Mould,et al.  Disease Progress Models , 2007 .

[48]  Melanie I. Stefan,et al.  BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models , 2010, BMC Systems Biology.

[49]  J. Tonascia,et al.  Budesonide and nedocromil did not improve lung function in children with asthma The Childhood Asthma Management Program Research Group. Long›term effects of budesonide or nedocromil in children , 2001 .

[50]  V. Lobanov,et al.  An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative , 2012, Journal of clinical pharmacology.

[51]  R. Barker,et al.  Modelling the natural history of Huntington's disease progression , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[52]  P. Mecocci,et al.  Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014 , 2014, Journal of internal medicine.

[53]  M. Riggs,et al.  Predicting Nonlinear Changes in Bone Mineral Density Over Time Using a Multiscale Systems Pharmacology Model , 2012, CPT: pharmacometrics & systems pharmacology.

[54]  Karline Soetaert,et al.  Inverse Modelling, Sensitivity and Monte Carlo Analysis in R Using Package FME , 2010 .

[55]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[56]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[57]  Innovation OR Stagnation Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .

[58]  S. Shechter,et al.  State‐space size considerations for disease‐progression models , 2013, Statistics in medicine.

[59]  P. Volberding,et al.  Zidovudine response relationships in early human immunodeficiency virus infection , 1993, Clinical pharmacology and therapeutics.

[60]  Klaus Romero,et al.  Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[61]  S. Visser,et al.  Implementation of Quantitative and Systems Pharmacology in Large Pharma , 2014, CPT: pharmacometrics & systems pharmacology.

[62]  D. Mould,et al.  Chapter 22 – Disease Progress Models , 2012 .